These top ASX 200 stocks could rise 25% to 60%

These shares could be cheap at current levels according to analysts.

Key points
  • Cochlear is poised for long-term growth driven by increasing global demand for hearing implants, supported by ageing populations and expanding healthcare access, with UBS setting a buy rating and a 25% upside price target of $350.
  • ResMed is capitalising on the vast undiagnosed sleep apnoea market, with innovations and a robust cloud ecosystem creating strong recurring revenue potential, as noted by Macquarie’s 25% upside prediction and $49.20 price target.
  • Xero, a leader in cloud accounting, is positioned for substantial growth with a vast untapped market of small businesses, offering a tremendous 60% upside potential according to Ord Minnett, driven by its expanding global footprint and digital adoption trends.

If you are looking for quality ASX 200 stocks to buy for big potential returns, then read on!

Listed below are three shares that analysts believe can rise very strongly from where they trade today.

After which, they have the potential to compound and build wealth for investors long into the future. Here's why they could be top picks right now:

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.

Image source: Getty Images

Cochlear Ltd (ASX: COH)

The first ASX 200 stock that could be a top buy is hearing implant leader Cochlear. It appears well position for growth over the long term thanks to rising demand for its devices on the back of ageing populations across the globe and broader access to hearing healthcare.

And with a robust balance sheet and a track record of delivering both earnings and dividend growth, Cochlear could be a blue chip to buy and hold onto for the next decade.

UBS currently rates Cochlear as a buy with a $350.00 price target. This implies potential upside of 25% for investors over the next 12 months.

ResMed Inc. (ASX: RMD)

Another ASX 200 stock to buy and hold could be ResMed. With more than one billion people worldwide estimated to suffer from sleep apnoea, and the vast majority undiagnosed, ResMed has a significant growth runway over the next decade and beyond. The company continues to innovate across masks, devices and software while benefiting from rising awareness and diagnosis rates. Its cloud-connected ecosystem creates sticky customer relationships and high recurring revenue. For investors seeking a defensive growth story backed by secular demand, ResMed could be a top pick.

Macquarie has an outperform rating and $49.20 price target on its shares. This suggests that upside of 25% is possible for investors from current levels.

Xero Ltd (ASX: XRO)

A third ASX 200 stock to consider buying and holding is Xero. It is one of the world's leading cloud accounting platforms and still has a huge global market to chase. With more than 4.5 million subscribers and NZ$2.7 billion in annualised monthly recurring revenue, the company remains in the early stages of penetrating a total addressable market estimated at around 100 million small businesses. As digital adoption accelerates in the UK, North America and Asia, Xero's subscription model and high customer lifetime value create a powerful long-term growth engine.

Ord Minnett is bullish on Xero's outlook. It recently put a buy rating and $200.00 price target on its shares. This implies potential upside of 60% for investors between now and this time next year.

Motley Fool contributor James Mickleboro has positions in Cochlear, ResMed, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Macquarie Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, and Xero. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Blue chip in a trolley with a man pushing it.
Blue Chip Shares

Commonwealth Bank vs BHP: Which ASX blue chip is the better buy in October?

Which company has the edge in my October ASX blue-chip comparison?

Read more »

Male hands holding Australian dollar banknotes, symbolising dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These large businesses have a lot of positives.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Blue Chip Shares

CBA vs Telstra: Which ASX blue-chip is better for passive income?

Commonwealth Bank or Telstra for your next passive income buy? I compare yields, franking, and my top pick for income…

Read more »

Woman and man at work looking at data on a tablet at work.
Opinions

Buy, hold, sell: BHP, CSL, and Westpac shares

I take a closer look at how I would approach these three major ASX shares today.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Blue Chip Shares

Could Wesfarmers shares reach $100 in 2027

I crunch the numbers to see what it would take for the retail giant to reach triple figures.

Read more »

Increasing stack of blue chips with a rising red arrow.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These major businesses are solid options for dividends…

Read more »

A woman in a sparkly dress smiles knowingly as she holds up two blue casino gambling chips in her hand next to her face.
Blue Chip Shares

2 ASX blue-chip shares that won't be hit by $100 oil

Higher oil hits some ASX shares harder than others.

Read more »

Couple on their laptop in their home kitchen.
Blue Chip Shares

Telstra vs NAB: Which ASX blue chip is the better buy?

I'm tipping Telstra over NAB for a better balance of income, franking, and recent share price momentum right now.

Read more »